Association between reduced folate carrier G80A polymorphism and methotrexate toxicity in childhood acute lymphoblastic leukemia: a meta-analysis

References

• Moricke A, Reiter A, Zimmermann M, et al. Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95. Blood 2008;111:4477–4489.
   PubMed Web of Science ®Google Scholar
• Lopez-Lopez E, Martin-Guerrero I, Ballesteros J, et al. A systematic review and meta-analysis of MTHFR polymorphisms in methotrexate toxicity prediction in pediatric acute lymphoblastic leukemia. Pharmacogenomics J 2012;13:498–506.
   PubMed Web of Science ®Google Scholar
• Radtke S, Zolk O, Renner B, et al. Germline genetic variations in methotrexate candidate genes are associated with pharmacokinetics, toxicity, and outcome in childhood acute lymphoblastic leukemia. Blood 2013;121:5145–5153.
   PubMed Web of Science ®Google Scholar
• Kishi S, Cheng C, French D, et al. Ancestry and pharmacogenetics of antileukemic drug toxicity. Blood 2007;109:4151–4157.
   PubMed Web of Science ®Google Scholar
• Imanishi H, Okamura N, Yagi M, et al. Genetic polymorphisms associated with adverse events and elimination of methotrexate in childhood acute lymphoblastic leukemia and malignant lymphoma. J Hum Genet 2007;52:166–171.
   PubMed Web of Science ®Google Scholar
• Pui CH, Robison LL, Look AT. Acute lymphoblastic leukaemia. Lancet 2008;371:1030–1043.
   PubMed Web of Science ®Google Scholar
• Krajinovic M, Moghrabi A. Pharmacogenetics of methotrexate. Pharmacogenomics 2004;5:819–834.
   PubMed Web of Science ®Google Scholar
• Zhao R, Diop-Bove N, Visentin M, et al. Mechanisms of membrane transport of folates into cells and across epithelia. Annu Rev Nutr 2011;31:177–201.
   PubMed Web of Science ®Google Scholar
• Chiusolo P, Giammarco S, Bellesi S, et al. The role of MTHFR and RFC1 polymorphisms on toxicity and outcome of adult patients with hematological malignancies treated with high-dose methotrexate followed by leucovorin rescue. Cancer Chemother Pharmacol 2012; 69:691–696.
   PubMed Web of Science ®Google Scholar
• Whetstine JR, Gifford AJ, Witt T, et al. Single nucleotide polymorphisms in the human reduced folate carrier: characterization of a high-frequency G/A variant at position 80 and transport properties of the His(27) and Arg(27) carriers. Clin Cancer Res 2001;7:3416–3422.
   PubMed Web of Science ®Google Scholar
• Chango A, Emery-Fillon N, de Courcy GP, et al. A polymorphism (80G-> A) in the reduced folate carrier gene and its associations with folate status and homocysteinemia. Mol Genet Metab 2000;70: 310–315.
   PubMed Web of Science ®Google Scholar
• Cheok MH, Evans WE. Acute lymphoblastic leukaemia: a model for the pharmacogenomics of cancer therapy. Nat Rev Cancer 2006;6:117–129.
   PubMed Web of Science ®Google Scholar
• Aldrin M, Raastad R, Tvete IF, et al. Antibiotic resistance in hospitals: a ward-specific random effect model in a low antibiotic consumption environment. Stat Med 2013;32:1407–1418.
   PubMed Web of Science ®Google Scholar
• de Deus DM, de Lima EL, Seabra SR, et al. Influence of methylenetetrahydrofolate reductase C677T, A1298C, and G80A polymorphisms on the survival of pediatric patients with acute lymphoblastic leukemia. Leuk Res Treat 2012;2012:292043.
   PubMedGoogle Scholar
• Lopez-Lopez E, Ballesteros J, Pinan MA, et al. Polymorphisms in the methotrexate transport pathway: a new tool for MTX plasma level prediction in pediatric acute lymphoblastic leukemia. Pharmacogenet Genomics 2013;23:53–61.
   PubMedGoogle Scholar
• Lopez-Lopez E, Martin-Guerrero I, Ballesteros J et al. Polymorphisms of the SLCO1B1 gene predict methotrexate-related toxicity in childhood acute lymphoblastic leukemia. Pediatr Blood Cancer 2011;57:612–619.
   PubMed Web of Science ®Google Scholar
• Horinouchi M, Yagi M, Imanishi H, et al. Association of genetic polymorphisms with hepatotoxicity in patients with childhood acute lymphoblastic leukemia or lymphoma. Pediatr Hematol Oncol 2010;27:344–354.
   PubMed Web of Science ®Google Scholar
• Faganel KB, Dolzan V, Grabnar I, et al. Relationship of the reduced folate carrier gene polymorphism G80A to methotrexate plasma concentration, toxicity, and disease outcome in childhood acute lymphoblastic leukemia. Leuk Lymphoma 2010;51:724–726.
   PubMed Web of Science ®Google Scholar
• Huang L, Tissing WJ, de Jonge R, et al. Polymorphisms in folate-related genes: association with side effects of high-dose methotrexate in childhood acute lymphoblastic leukemia. Leukemia 2008;22: 1798–1800.
   PubMed Web of Science ®Google Scholar
• Shimasaki N, Mori T, Torii C, et al. Influence of MTHFR and RFC1 polymorphisms on toxicities during maintenance chemotherapy for childhood acute lymphoblastic leukemia or lymphoma. J Pediatr Hematol Oncol 2008;30:347–352.
   PubMed Web of Science ®Google Scholar
• Pakakasama S, Kanchanakamhaeng K, Kajanachumpol S, et al. Genetic polymorphisms of folate metabolic enzymes and toxicities of high dose methotrexate in children with acute lymphoblastic leukemia. Ann Hematol 2007;86:609–611.
   PubMed Web of Science ®Google Scholar
• Kishi S, Griener J, Cheng C, et al. Homocysteine, pharmacogenetics, and neurotoxicity in children with leukemia. J Clin Oncol 2003;21: 3084–3091.
   PubMed Web of Science ®Google Scholar
• Faganel KB, Grabnar I, Bohanec GP, et al. Association of genetic polymorphism in the folate metabolic pathway with methotrexate pharmacokinetics and toxicity in childhood acute lymphoblastic leukaemia and malignant lymphoma. Eur J Clin Pharmacol 2011;67:993–1006.
   PubMed Web of Science ®Google Scholar
• Gregers J, Christensen IJ, Dalhoff K, et al. The association of reduced folate carrier 80G> A polymorphism to outcome in childhood acute lymphoblastic leukemia interacts with chromosome 21 copy number. Blood 2010;115:4671–4677.
   PubMed Web of Science ®Google Scholar
• Laverdiere C, Chiasson S, Costea I, et al. Polymorphism G80A in the reduced folate carrier gene and its relationship to methotrexate plasma levels and outcome of childhood acute lymphoblastic leukemia. Blood 2002;100:3832–3834.
   PubMed Web of Science ®Google Scholar
• Shimasaki N, Mori T, Samejima H, et al. Effects of methylenetetrahydrofolate reductase and reduced folate carrier 1 polymorphisms on high-dose methotrexate-induced toxicities in children with acute lymphoblastic leukemia or lymphoma. J Pediatr Hematol Oncol 2006;28:64–68.
   PubMed Web of Science ®Google Scholar
• Pui CH, Evans WE. Treatment of acute lymphoblastic leukemia. N Engl J Med 2006;354:166–178.
   PubMed Web of Science ®Google Scholar
• Schmiegelow K. Advances in individual prediction of methotrexate toxicity: a review. Br J Haematol 2009;146:489–503.
   PubMed Web of Science ®Google Scholar
• Gervasini G. Polymorphisms in methotrexate pathways: what is clinically relevant, what is not, and what is promising. Curr Drug Metab 2009;10:547–566.
   PubMed Web of Science ®Google Scholar
• Yang L, Hu X, Xu L. Impact of methylenetetrahydrofolate reductase (MTHFR) polymorphisms on methotrexate-induced toxicities in acute lymphoblastic leukemia: a meta-analysis. Tumour Biol 2012;33: 1445–1454.
   PubMed Web of Science ®Google Scholar